+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Diabetic Retinopathy Market by Product Type, Diabetic Type, Patient Type, End-User - Global Forecast to 2030- Product Image
Diabetic Retinopathy Market by Product Type, Diabetic Type, Patient Type, End-User - Global Forecast to 2030- Product Image
Sale

Diabetic Retinopathy Market by Product Type, Diabetic Type, Patient Type, End-User - Global Forecast to 2030

  • PDF Icon

    Report

  • 183 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5788863
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The diabetic retinopathy market is at a pivotal stage, shaped by evolving clinical needs, advanced technologies, and shifting reimbursement policies. Senior decision-makers are navigating a complex landscape that demands both timely insights and actionable strategies to capture emerging opportunities and mitigate barriers in diabetic eye care.

Market Snapshot: Diabetic Retinopathy Market Size and Growth

The Diabetic Retinopathy Market grew from USD 9.07 billion in 2024 to USD 9.62 billion in 2025, supported by a projected CAGR of 6.21% and an anticipated market value of USD 13.02 billion by 2030. Anti-VEGF agents, corticosteroid implants, and sophisticated imaging technologies shape the competitive environment, while evolving global demographics and healthcare expenditure patterns drive demand across key territories. The market responds to rising diabetes prevalence with multi-modal therapies and accelerated adoption of digital diagnostics, further intensifying the pace of innovation and competition among stakeholders.

Scope & Segmentation

  • Product Types: Anti-VEGF agents (Aflibercept, Bevacizumab, Ranibizumab), corticosteroids (Dexamethasone, Triamcinolone), laser equipment, and surgical implants
  • Disease Classification: Non-proliferative diabetic retinopathy, proliferative diabetic retinopathy
  • Patient Types: Adult and pediatric patient groups
  • End Users: Ambulatory surgical centers, general clinics, specialty clinics, private hospitals, and public hospitals
  • Regional Coverage: Americas (United States—including California, Texas, New York, Florida, Illinois, Pennsylvania, Ohio—Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (United Kingdom, Germany, France, Russia, Italy, Spain, United Arab Emirates, Saudi Arabia, South Africa, Denmark, Netherlands, Qatar, Finland, Sweden, Nigeria, Egypt, Turkey, Israel, Norway, Poland, Switzerland), Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan)
  • Technology Applications: Integration of artificial intelligence in imaging, sustained-release drug delivery, digitally enabled remote monitoring, and teleophthalmology for enhanced specialist access
  • Key Companies: AbbVie Inc., AEYE Health, Amgen Inc., ANI Pharmaceuticals, Inc., Bausch + Lomb Corporation, Bayer AG, BCN Peptides, S.A.U., Boehringer Ingelheim International GmbH, Clearside Biomedical, Inc., Eli Lilly and Company, Eyenuk, Inc., EyePoint Pharmaceuticals, Inc., F. Hoffmann-La Roche AG, Kodiak Sciences Inc., Novartis AG, Ocugen, Inc., Ocular Therapeutix, Inc., Ocuphire Pharma, Inc., OcuTerra Therapeutics, Opthea Limited, Oxurion NV, Pfizer, Inc., Regeneron Pharmaceuticals, Inc., REGENXBIO Inc., RetinaRisk, RETMARKER, Samsung Biologics Co., Ltd.

Key Takeaways for Strategic Decision-Makers

  • Market transformation is driven by synergy between pharmacologic innovation and digital imaging, facilitating timely detection and intervention.
  • Diversification in treatment approaches, such as combination therapies and technological integration, provides more choices to clinicians while increasing market fragmentation.
  • Evolving patient demographics, with rising juvenile diabetes rates, prompt greater focus on pediatric care solutions and age-specific drug delivery mechanisms.
  • Innovation in care models, including teleophthalmology and AI-enabled diagnostic platforms, extends access in underserved regions and supports adherence in chronic management.
  • Strategic alignment between device manufacturers and digital health partners accelerates product development cycles and enhances data-driven insights for market positioning.
  • Regional disparities in infrastructure and regulatory processes require flexible market entry and resource allocation strategies tailored to local contexts.

Tariff Impact: U.S. Regulatory Dynamics and Global Supply Chains

The introduction of new U.S. tariffs in 2025 creates added cost complexity for ophthalmic device imports, prompting manufacturers to realign pricing, enhance local sourcing, and adapt procurement strategies. Healthcare providers must evaluate bundled payments and value-based contracts to counteract increased expenses, while market participants engage policymakers and payers to seek tariff relief or alternative regulatory pathways for critical devices. Supply chain resilience—achieved by diversifying manufacturing bases and forging local alliances—emerges as a priority amid ongoing regulatory changes, with direct implications for competitive agility and commercial stability.

Methodology & Data Sources

This report synthesizes primary interviews with industry leaders and clinicians, paired with comprehensive secondary research from peer-reviewed journals, regulatory databases, and market filings. Analysis incorporates both quantitative data and qualitative expert validation, ensuring segment definitions, market trends, and forecasts are solidly substantiated. Rigorous data triangulation and multi-analyst review cycles add further reliability to findings.

Why This Report Matters

  • Enables executives to benchmark evolving technologies and competitive movements for informed market entry and product investment decisions.
  • Delivers actionable analysis on market segmentation, regulatory shifts, and pathway innovation, supporting long-term planning and risk mitigation.
  • Guides resource allocation with up-to-date regional insights and evolving reimbursement trends for enhanced leadership positioning.

Conclusion

As the diabetic retinopathy market continues to evolve, success will depend on proactive adoption of new therapies, hybrid care models, and adaptive regional strategies. This report provides the essential clarity needed for confident, data-driven decision-making in an increasingly dynamic environment.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Diabetic Retinopathy Market, by Product Type
8.1. Introduction
8.2. Anti-VEGF Agents
8.2.1. Aflibercept
8.2.2. Bevacizumab
8.2.3. Ranibizumab
8.3. Corticosteroids
8.3.1. Dexamethasone
8.3.2. Triamcinolone
8.4. Laser Equipment
8.5. Surgical Implants
9. Diabetic Retinopathy Market, by Diabetic Type
9.1. Introduction
9.2. Non-Proliferative Diabetic Retinopathy
9.3. Proliferative Diabetic Retinopathy
10. Diabetic Retinopathy Market, by Patient Type
10.1. Introduction
10.2. Adult
10.3. Pediatric
11. Diabetic Retinopathy Market, by End-User
11.1. Introduction
11.2. Ambulatory Surgical Centers
11.3. Clinics
11.3.1. General Clinics
11.3.2. Specialty Clinics
11.4. Hospitals
11.4.1. Private Hospitals
11.4.2. Public Hospitals
12. Americas Diabetic Retinopathy Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Diabetic Retinopathy Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Diabetic Retinopathy Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. AbbVie Inc.
15.3.2. AEYE Health
15.3.3. Amgen Inc.
15.3.4. ANI Pharmaceuticals, Inc.
15.3.5. Bausch + Lomb Corporation
15.3.6. Bayer AG
15.3.7. BCN Peptides, S.A.U.
15.3.8. Boehringer Ingelheim International GmbH
15.3.9. Clearside Biomedical, Inc.
15.3.10. Eli Lilly and Company
15.3.11. Eyenuk, Inc.
15.3.12. EyePoint Pharmaceuticals, Inc.
15.3.13. F. Hoffmann-La Roche AG
15.3.14. Kodiak Sciences Inc.
15.3.15. Novartis AG
15.3.16. Ocugen, Inc.
15.3.17. Ocular Therapeutix, Inc.
15.3.18. Ocuphire Pharma, Inc.
15.3.19. OcuTerra Therapeutics
15.3.20. Opthea Limited
15.3.21. Oxurion NV
15.3.22. Pfizer, Inc.
15.3.23. Regeneron Pharmaceuticals, Inc.
15.3.24. REGENXBIO Inc.
15.3.25. RetinaRisk
15.3.26. RETMARKER
15.3.27. Samsung Biologics Co., Ltd.
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. DIABETIC RETINOPATHY MARKET MULTI-CURRENCY
FIGURE 2. DIABETIC RETINOPATHY MARKET MULTI-LANGUAGE
FIGURE 3. DIABETIC RETINOPATHY MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES DIABETIC RETINOPATHY MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES DIABETIC RETINOPATHY MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. DIABETIC RETINOPATHY MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. DIABETIC RETINOPATHY MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. DIABETIC RETINOPATHY MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY AFLIBERCEPT, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY BEVACIZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY RANIBIZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY DEXAMETHASONE, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY TRIAMCINOLONE, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY LASER EQUIPMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY SURGICAL IMPLANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY NON-PROLIFERATIVE DIABETIC RETINOPATHY, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY PROLIFERATIVE DIABETIC RETINOPATHY, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY GENERAL CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 34. AMERICAS DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 43. UNITED STATES DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 44. UNITED STATES DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 45. UNITED STATES DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 46. UNITED STATES DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 47. UNITED STATES DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 48. UNITED STATES DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 49. UNITED STATES DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 50. UNITED STATES DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 51. UNITED STATES DIABETIC RETINOPATHY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 52. CANADA DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 53. CANADA DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 54. CANADA DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 55. CANADA DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 56. CANADA DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 57. CANADA DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 58. CANADA DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 59. CANADA DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 60. MEXICO DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 61. MEXICO DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 62. MEXICO DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 63. MEXICO DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 64. MEXICO DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 65. MEXICO DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 66. MEXICO DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 67. MEXICO DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 68. BRAZIL DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 69. BRAZIL DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 70. BRAZIL DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 71. BRAZIL DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 72. BRAZIL DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 73. BRAZIL DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 74. BRAZIL DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 75. BRAZIL DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 76. ARGENTINA DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 77. ARGENTINA DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 78. ARGENTINA DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 79. ARGENTINA DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 80. ARGENTINA DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 81. ARGENTINA DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 82. ARGENTINA DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 83. ARGENTINA DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 84. EUROPE, MIDDLE EAST & AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 85. EUROPE, MIDDLE EAST & AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 86. EUROPE, MIDDLE EAST & AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 87. EUROPE, MIDDLE EAST & AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 88. EUROPE, MIDDLE EAST & AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 89. EUROPE, MIDDLE EAST & AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 90. EUROPE, MIDDLE EAST & AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 91. EUROPE, MIDDLE EAST & AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 92. EUROPE, MIDDLE EAST & AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 93. UNITED KINGDOM DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 94. UNITED KINGDOM DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 95. UNITED KINGDOM DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 96. UNITED KINGDOM DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 97. UNITED KINGDOM DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 98. UNITED KINGDOM DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 99. UNITED KINGDOM DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 100. UNITED KINGDOM DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 101. GERMANY DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 102. GERMANY DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 103. GERMANY DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 104. GERMANY DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 105. GERMANY DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 106. GERMANY DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 107. GERMANY DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 108. GERMANY DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 109. FRANCE DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 110. FRANCE DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 111. FRANCE DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 112. FRANCE DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 113. FRANCE DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 114. FRANCE DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 115. FRANCE DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 116. FRANCE DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 117. RUSSIA DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 118. RUSSIA DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 119. RUSSIA DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 120. RUSSIA DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 121. RUSSIA DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 122. RUSSIA DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 123. RUSSIA DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 124. RUSSIA DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 125. ITALY DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 126. ITALY DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 127. ITALY DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 128. ITALY DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 129. ITALY DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 130. ITALY DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 131. ITALY DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 132. ITALY DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 133. SPAIN DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 134. SPAIN DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 135. SPAIN DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 136. SPAIN DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 137. SPAIN DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 138. SPAIN DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 139. SPAIN DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 140. SPAIN DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 141. UNITED ARAB EMIRATES DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 142. UNITED ARAB EMIRATES DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 143. UNITED ARAB EMIRATES DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 144. UNITED ARAB EMIRATES DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 145. UNITED ARAB EMIRATES DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 146. UNITED ARAB EMIRATES DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 147. UNITED ARAB EMIRATES DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 148. UNITED ARAB EMIRATES DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 149. SAUDI ARABIA DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 150. SAUDI ARABIA DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 151. SAUDI ARABIA DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 152. SAUDI ARABIA DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 153. SAUDI ARABIA DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 154. SAUDI ARABIA DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 155. SAUDI ARABIA DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 156. SAUDI ARABIA DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 157. SOUTH AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 158. SOUTH AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 159. SOUTH AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 160. SOUTH AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 161. SOUTH AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 162. SOUTH AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 163. SOUTH AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 164. SOUTH AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 165. DENMARK DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 166. DENMARK DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 167. DENMARK DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 168. DENMARK DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 169. DENMARK DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 170. DENMARK DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 171. DENMARK DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 172. DENMARK DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 173. NETHERLANDS DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 174. NETHERLANDS DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 175. NETHERLANDS DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 176. NETHERLANDS DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 177. NETHERLANDS DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 178. NETHERLANDS DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 179. NETHERLANDS DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 180. NETHERLANDS DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 181. QATAR DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 182. QATAR DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 183. QATAR DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 184. QATAR DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 185. QATAR DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 186. QATAR DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 187. QATAR DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 188. QATAR DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 189. FINLAND DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 190. FINLAND DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 191. FINLAND DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 192. FINLAND DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 193. FINLAND DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 194. FINLAND DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 195. FINLAND DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 196. FINLAND DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 197. SWEDEN DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 198. SWEDEN DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 199. SWEDEN DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 200. SWEDEN DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 201. SWEDEN DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 202. SWEDEN DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 203. SWEDEN DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 204. SWEDEN DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 205. NIGERIA DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 206. NIGERIA DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 207. NIGERIA DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 208. NIGERIA DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 209. NIGERIA DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 210. NIGERIA DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 211. NIGERIA DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 212. NIGERIA DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 213. EGYPT DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 214. EGYPT DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 215. EGYPT DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 216. EGYPT DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 217. EGYPT DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 218. EGYPT DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 219. EGYPT DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 220. EGYPT DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 221. TURKEY DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 222. TURKEY DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 223. TURKEY DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 224. TURKEY DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 225. TURKEY DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 226. TURKEY DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 227. TURKEY DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 228. TURKEY DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 229. ISRAEL DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 230. ISRAEL DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 231. ISRAEL DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 232. ISRAEL DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 233. ISRAEL DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 234. ISRAEL DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 235. ISRAEL DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 236. ISRAEL DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 237. NORWAY DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 238. NORWAY DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 239. NORWAY DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 240. NORWAY DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 241. NORWAY DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 242. NORWAY DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 243. NORWAY DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 244. NORWAY DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 245. POLAND DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 246. POLAND DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 247. POLAND DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 248. POLAND DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 249. POLAND DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 250. POLAND DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 251. POLAND DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 252. POLAND DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 253. SWITZERLAND DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 254. SWITZERLAND DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 255. SWITZERLAND DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 256. SWITZERLAND DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 257. SWITZERLAND DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 258. SWITZERLAND DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 259. SWITZERLAND DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 260. SWITZERLAND DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 261. ASIA-PACIFIC DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 262. ASIA-PACIFIC DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 263. ASIA-PACIFIC DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 264. ASIA-PACIFIC DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 265. ASIA-PACIFIC DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 266. ASIA-PACIFIC DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 267. ASIA-PACIFIC DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 268. ASIA-PACIFIC DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 269. ASIA-PACIFIC DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 270. CHINA DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 271. CHINA DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 272. CHINA DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 273. CHINA DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 274. CHINA DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 275. CHINA DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 276. CHINA DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 277. CHINA DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 278. INDIA DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 279. INDIA DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 280. INDIA DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 281. INDIA DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 282. INDIA DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 283. INDIA DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 284. INDIA DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 285. INDIA DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 286. JAPAN DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 287. JAPAN DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 288. JAPAN DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 289. JAPAN DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 290. JAPAN DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 291. JAPAN DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 292. JAPAN DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 293. JAPAN DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 294. AUSTRALIA DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 295. AUSTRALIA DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 296. AUSTRALIA DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 297. AUSTRALIA DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 298. AUSTRALIA DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 299. AUSTRALIA DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 300. AUSTRALIA DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 301. AUSTRALIA DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 302. SOUTH KOREA DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 303. SOUTH KOREA DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 304. SOUTH KOREA DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 305. SOUTH KOREA DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 306. SOUTH KOREA DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 307. SOUTH KOREA DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 308. SOUTH KOREA DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 309. SOUTH KOREA DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 310. INDONESIA DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 311. INDONESIA DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 312. INDONESIA DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 313. INDONESIA DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 314. INDONESIA DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 315. INDONESIA DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 316. INDONESIA DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 317. INDONESIA DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 318. THAILAND DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 319. THAILAND DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 320. THAILAND DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 321. THAILAND DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 322. THAILAND DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 323. THAILAND DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 324. THAILAND DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 325. THAILAND DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 326. PHILIPPINES DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 327. PHILIPPINES DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 328. PHILIPPINES DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 329. PHILIPPINES DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 330. PHILIPPINES DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 331. PHILIPPINES DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 332. PHILIPPINES DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 333. PHILIPPINES DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 334. MALAYSIA DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 335. MALAYSIA DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 336. MALAYSIA DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 337. MALAYSIA DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 338. MALAYSIA DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 339. MALAYSIA DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 340. MALAYSIA DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 341. MALAYSIA DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 342. SINGAPORE DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 343. SINGAPORE DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 344. SINGAPORE DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLI

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Diabetic Retinopathy market report include:
  • AbbVie Inc.
  • AEYE Health
  • Amgen Inc.
  • ANI Pharmaceuticals, Inc.
  • Bausch + Lomb Corporation
  • Bayer AG
  • BCN Peptides, S.A.U.
  • Boehringer Ingelheim International GmbH
  • Clearside Biomedical, Inc.
  • Eli Lilly and Company
  • Eyenuk, Inc.
  • EyePoint Pharmaceuticals, Inc.
  • F. Hoffmann-La Roche AG
  • Kodiak Sciences Inc.
  • Novartis AG
  • Ocugen, Inc.
  • Ocular Therapeutix, Inc.
  • Ocuphire Pharma, Inc.
  • OcuTerra Therapeutics
  • Opthea Limited
  • Oxurion NV
  • Pfizer, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • REGENXBIO Inc.
  • RetinaRisk
  • RETMARKER
  • Samsung Biologics Co., Ltd.

Table Information

Report AttributeDetails
No. of Pages183
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 9.62 Billion
Forecasted Market Value ( USD ) by 2030 $ 13.02 Billion
Compound Annual Growth Rate6.2%
Regions CoveredGlobal
No. of Companies Mentioned28

Related Topics

Related Reports

Diabetic Retinopathy Market Size, Share & Trends Analysis Report by Type (Proliferative Diabetic Retinopathy), Management (Anti-VEGF, Intraocular Steroid Injection, Laser Surgery, Vitrectomy), Region and Segment Forecasts, 2025 - 2030 - Product Image

Diabetic Retinopathy Market Size, Share & Trends Analysis Report by Type (Proliferative Diabetic Retinopathy), Management (Anti-VEGF, Intraocular Steroid Injection, Laser Surgery, Vitrectomy), Region and Segment Forecasts, 2025 - 2030

  • Report
  • 100 Pages
  • Global
From
Diabetic Retinopathy Screening Solution Market by End User, Product Type, Deployment, Technology - Global Forecast to 2030 - Product Image

Diabetic Retinopathy Screening Solution Market by End User, Product Type, Deployment, Technology - Global Forecast to 2030

  • Report
  • 187 Pages
  • Global
From
Diabetic Retinopathy Treatment - Global Strategic Business Report - Product Image

Diabetic Retinopathy Treatment - Global Strategic Business Report

  • Report
  • 273 Pages
  • Global
From
Diabetic Retinopathy Treatment Market Size Analysis Report - Market Share, Forecast Trends and Outlook (2025-2034) - Product Image

Diabetic Retinopathy Treatment Market Size Analysis Report - Market Share, Forecast Trends and Outlook (2025-2034)

  • Report
  • 400 Pages
  • Global
From
Proliferative Diabetic Retinopathy (PDR) Market Report 2025 - Product Image

Proliferative Diabetic Retinopathy (PDR) Market Report 2025

  • Report
  • 200 Pages
  • Global
From

About the Diabetic Retinopathy Market

Diabetic Retinopathy (DR) is a medical condition that affects the eyes of people with diabetes. It is caused by damage to the blood vessels in the retina, the light-sensitive layer of tissue at the back of the eye. DR can lead to vision loss and blindness if left untreated. Optical imaging technologies, such as optical coherence tomography (OCT) and fundus photography, are used to diagnose and monitor DR. These technologies allow for early detection and treatment of DR, which can help to reduce the risk of vision loss. In addition to imaging technologies, there are a number of treatments available for DR, including laser photocoagulation, intravitreal injections, and vitrectomy. These treatments can help to reduce the risk of vision loss and improve vision in those with DR. The DR market is a rapidly growing market, driven by the increasing prevalence of diabetes and the need for early detection and treatment of DR. Companies in the DR market include Carl Zeiss Meditec, Topcon Corporation, Optos, Nidek, and Heidelberg Engineering. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.